Elranatamab Biosimilar Bispecific Antibody (BCMA × CD3) for Research

Cat No.: GMP-Bios-ab-663

Pre-Made Elranatamab biosimilar, Whole mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.Elranatamab (PF-06863135) is a bispecific antibody (IgG2a) targeting the B-cell maturation antigen (BCMA) on multiple myeloma (MM) cells and CD3 on T cells, bridging them together to activate an immune response.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-663-1mg 1mg 486.5
GMP-Bios-ab-663-10mg 10mg
GMP-Bios-ab-663-100mg 100mg
GMP-Bios-ab-663-xmg >100mg



Product Details

Products Name (INN Index) Pre-Made Elranatamab biosimilar, Whole mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody
INN Name Elranatamab
TargetTNFRSF17;CD3E
FormatBispecific Whole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG2;IgG2
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2021
Year Recommendedna
CompaniesPfizer
Conditions Approvedna
Conditions ActiveMultiple myeloma
Conditions Discontinuedna
Development Techna



About target - TNFRSF17

1. Protein Tumor necrosis factor receptor superfamily member 17

2. Gene TNFRSF17

3. Organism Homo sapiens (Human)

Function

Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK.